Cisplatin ototoxicity histopathology

Temporal bone histopathology of furosemide ototoxicity

OBJECTIVES To describe the human temporal bone pathology in two patients who incurred furosemide induced ototoxicity. PATIENTS 1) A 46-year-old woman in acute liver and renal failure treated with high doses of furosemide for anasarca who developed a rapidly progressive severe-to-profound asymmetric sensorineural hearing loss. 2) A 65-year-old woman with undifferentiated small cell carcinoma o...

Cisplatin-induced Ototoxicity. Pharmacokinetics, Prediction and Prevention

[Genetic background of cisplatin induced ototoxicity].

BACKGROUND Cisplatin induced ototoxicity is a serious adverse effect of cisplatin therapy. Cisplatin induced ototoxicity shows significant interindividual variability. This variability is probably based on genetic background. Recent papers describe association of cisplatin ototoxicity with allelic variants of glutathion-S-transferase coding genes. PATIENTS AND METHODS We have analyzed 55 pati...

Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection

Evidence of significant hearing loss during the early days of use of cisplatin as a chemotherapeutic agent in cancer patients has stimulated research into the causes and treatment of this side effect. It has generally been accepted that hearing loss is produced by excessive generation of reactive oxygen species (ROS) in cell of the cochlea, which led to the development of various antioxidants a...

Mechanisms of cisplatin ototoxicity: theoretical review.

INTRODUCTION Cisplatin is an effective chemotherapeutic agent commonly used in the treatment of malignant tumours, but ototoxicity is a significant side effect. OBJECTIVES To discuss the mechanisms of cisplatin ototoxicity and subsequent cell death, and to present the results of experimental studies. MATERIAL AND METHODS We conducted a systematic search for data published in national and in...